Vicebio is a UniQuest start-up company. It is developing new protein-based vaccines for life-threatening non-pandemic respiratory viral infectious diseases using UQ’s Molecular Clamp platform technology.

Vaxxas is a UniQuest start-up company commercializing a novel vaccination technology that dramatically enhances the performance of existing and next-generation vaccines. Vaxxas' HD-MAP technology uses a patch with thousands of vaccine-coated microprojections that is applied to the skin for a few seconds to efficiently deliver vaccine to the abundant immune cells immediately below the skin surface.

Proud member of UQ's COVID-19 rapid response molecular clamp vaccine deal team from January 2020.Leadership of commercialisation of Life Sciences related intellectual property and expertise at UniQuest to achieve strategic and operational objectives. Life Sciences spans from healthcare, therapeutics, biomedical devices, diagnostics, biological sciences, bio-derived products, agriculture and food. Adding value to The University of Queensland through business development and key… Show more Proud member of UQ's COVID-19 rapid response molecular clamp vaccine deal team from January 2020.Leadership of commercialisation of Life Sciences related intellectual property and expertise at UniQuest to achieve strategic and operational objectives. Life Sciences spans from healthcare, therapeutics, biomedical devices, diagnostics, biological sciences, bio-derived products, agriculture and food. Adding value to The University of Queensland through business development and key account management leading to the commercialisation of expertise and intellectual property. Show less

Lead strategy development and implementation of technology commercialisation at UQ's Australian Institute for Bioengineering and Nanotechnology (AIBN) and Queensland Brain Institute (QBI).Lead and manage small high performance teams on commercialisation projects, deployed on 52 patent families and over 200 discoveries at AIBN, and managing staff directly as well as 15 project team members indirectly.Led and closed over 20 deals with aggregate of over $43m research income whilst… Show more Lead strategy development and implementation of technology commercialisation at UQ's Australian Institute for Bioengineering and Nanotechnology (AIBN) and Queensland Brain Institute (QBI).Lead and manage small high performance teams on commercialisation projects, deployed on 52 patent families and over 200 discoveries at AIBN, and managing staff directly as well as 15 project team members indirectly.Led and closed over 20 deals with aggregate of over $43m research income whilst retaining potential for licensing revenue from future products.Led and successfully pitched for over $2m of venture capital in AIBN's first 3 start-up companies. Show less

A UniQuest start-up company based on UQ intellectual property with venture capital backing that remains in stealth.

Dendright is a UniQuest start-up company. It is a clinical-stage biotechnology company developing a tolerizing immunotherapy for the treatment of patients with rheumatoid arthritis (RA). In January 2017, the company extended its R&D Collaboration and Option to License Agreement with US-based Janssen Biotech, Inc. to progress Dendright’s lead drug candidate for RA to the clinic. In addition, the not-for-profit organisation Arthritis Queensland contributed funding to the clinical program.… Show more Dendright is a UniQuest start-up company. It is a clinical-stage biotechnology company developing a tolerizing immunotherapy for the treatment of patients with rheumatoid arthritis (RA). In January 2017, the company extended its R&D Collaboration and Option to License Agreement with US-based Janssen Biotech, Inc. to progress Dendright’s lead drug candidate for RA to the clinic. In addition, the not-for-profit organisation Arthritis Queensland contributed funding to the clinical program. Key provisions in the 2013 R&D Collaboration and Option to License Agreement remain unchanged. Under the terms of the agreement, Dendright receives funding and, in return, Janssen has an option to the exclusive worldwide rights to develop and commercialise Dendright’s RA immunotherapy. In addition to an option payment, Dendright is eligible to receive certain development and sales milestone payments as well as tiered royalties on sales. Dendright will be responsible for completing the phase 1 clinical trial in Australia. Janssen will be responsible for further development, clinical and regulatory filing activities. Dendright is wholly owned by UniQuest Pty Ltd, the main commercialisation company of The University of Queensland.Dendright’s core technology patent was granted by the USPTO in 2015. The company has also secured the grant of related patents in Australia, Canada and China with prosecution continuing in Europe.By targeting the cause of autoimmune disease rather than treating the symptoms, Dendright’s immunotherapies offer the potential for long-lasting treatment by working with the body’s own immune system to fight disease. Show less

Nexgen Plants is a UniQuest start-up company. It is commercializing a novel platform technology that enables virus resistant plant varieties to be developed for major food, fibre, energy and ornamental crops used around the world.

AquaHydrex is a UniQuest start-up company. It is developing a unique electro-chemical platform technology capable of transforming significant industrial gas and energy market segments. It was established by UniQuest in 2012 when it was commercialising for the University of Wollongong and attracted investment from Chicago based True North Venture Partners. The technology originated from the ARC Centre of Excellence for Electromaterials Science (ACES) and was licensed from both the University of… Show more AquaHydrex is a UniQuest start-up company. It is developing a unique electro-chemical platform technology capable of transforming significant industrial gas and energy market segments. It was established by UniQuest in 2012 when it was commercialising for the University of Wollongong and attracted investment from Chicago based True North Venture Partners. The technology originated from the ARC Centre of Excellence for Electromaterials Science (ACES) and was licensed from both the University of Wollongong and Monash University. Show less

Tenasitech is a UniQuest start-up company commercialising scratch-resistant plastic nanoparticle additives. November 2020 acquired by RTP Company to add new products to its portfolio, initially targeting acrylic, polyamide and polyester resin materials. RTP is a US-based leading global compounder of custom engineered thermoplastics. Founding Board member in 2007 and involved in raising capital from Uniseed and Brisbane Angels, a number of co-development agreements with end-users in the… Show more Tenasitech is a UniQuest start-up company commercialising scratch-resistant plastic nanoparticle additives. November 2020 acquired by RTP Company to add new products to its portfolio, initially targeting acrylic, polyamide and polyester resin materials. RTP is a US-based leading global compounder of custom engineered thermoplastics. Founding Board member in 2007 and involved in raising capital from Uniseed and Brisbane Angels, a number of co-development agreements with end-users in the US, Europe and Australia, and attracting non-diluting capital from Queensland and Australian Government innovation and product development programs. Show less

Directly involved in therapeutic antibody deal-making with Genzyme (antibody library license), Xerion Pharmaceuticals (allergy target validation) and Incyte (access to Incyte’s LifeSeq® database with options to license antibody target IPR). Post-deal alliance manager for therapeutic antibody deals with Chugai Pharmaceuticals (a Japanese subsidiary of Hoffmann–La Roche) and the second alliance with Merck & Co (West Point, Pennsylvania).Directly involved in antibody biochip… Show more Directly involved in therapeutic antibody deal-making with Genzyme (antibody library license), Xerion Pharmaceuticals (allergy target validation) and Incyte (access to Incyte’s LifeSeq® database with options to license antibody target IPR). Post-deal alliance manager for therapeutic antibody deals with Chugai Pharmaceuticals (a Japanese subsidiary of Hoffmann–La Roche) and the second alliance with Merck & Co (West Point, Pennsylvania).Directly involved in antibody biochip deal-making with Randox (Belfast, Northern Ireland) and Zyomyx (Hayward, California), both were collaborative R&D technology alliances. Show less